Presentation ACC 2018 Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants Presenter: Steve Deitelzweig March 12, 2018 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Coronary CAD Pharma Heart Rhythm Atrial Fibrillation Presentation ACC 2018 Up Next Presentation ACC 2018 A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial) Presenter: Mehdi H. Shishehbor March 12, 2018 More slides + Presentation ACC 2018 High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS Presenter: Sonia S. Anand March 11, 2018 Presentation ACC 2018 6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE) Presenter: Hyeon-Cheol Gwon March 12, 2018 We Recommend
Presentation ACC 2018 A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial) Presenter: Mehdi H. Shishehbor March 12, 2018
Presentation ACC 2018 High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS Presenter: Sonia S. Anand March 11, 2018
Presentation ACC 2018 6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE) Presenter: Hyeon-Cheol Gwon March 12, 2018